- A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation2011 | Second Faculty of Medicine
- GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)2019 | Second Faculty of Medicine
- Causal therapy of cystic fibrosis2014 | Second Faculty of Medicine
- Therapeutic strategies in cystic fibrosis2014 | Second Faculty of Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)2014 | Second Faculty of Medicine
- The future of cystic fibrosis care: a global perspective2020 | Second Faculty of Medicine
- CFTR protein modulators2019 | Second Faculty of Medicine
- The current view of the diagnosis and new treatment options of Cystic Fibrosis2016 | Faculty of Medicine in Pilsen
- Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR2015 | Second Faculty of Medicine
- Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment2019 | Second Faculty of Medicine
- Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells2021 | Second Faculty of Medicine